Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis

Abstract

TP53 may be an independent predictor of response to immunotherapy in LUAD, and patients with TP53 mutations have higher immunogenicity and immune cell infiltration.